We help scientists commercialise their research and bring it to a global audience.
Location: China, Hong Kong, Kowloon
Employees: 11-50
Founded date: 2020
Investment Type: Venture Capital
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| 20.10.2025 | Cyclana Bi... | cyclanabio.com | $6.74M | United Kin... |
Mentions in press and media 15
| Date | Title | Description |
| 05.03.2026 | Wilbe opens White City lab in London to remove infrastructure bottlenecks for science startups | Wilbe, the venture fund and platform that trains and backs scientists to build companies from day one, today announces the launch of its first dedicated lab facility in White City, London. To date, Wilbe has trained more than 1,400 scientis... |
| 22.10.2025 | New Era for Women's Health: Cyclana Bio's £5M Funding Drives Tissue-Level Drug Innovation | Cyclana Bio, a cutting-edge Cambridge biotech, has closed a substantial £5 million pre-seed funding round. Co-led by NfX and Eka VC, this capital injection fuels a transformative mission. The company pioneers tissue-level drug discovery, ta... |
| 22.10.2025 | Cyclana Bio: £5 Million Raised To Advance Drug Discovery For Endometriosis Through Whole-Tissue Research Platform | Cyclana Bio, a biotechnology company pioneering tissue-level approaches to women’s health, announced the closing of a £5 million pre-seed funding round, co-led by NfX and Eka VC, with participation from Cocoa VC, Wilbe, and several angel in... |
| 20.10.2025 | Cyclana Bio Raises £5M in Pre-Seed Funding | Cyclana Bio, a Cambridge, UK-based biotechnology company pioneering tissue-level approaches to women’s health, closed a £5M pre-seed funding round. The round was co-led by NfX and Eka VC, with participation from Cocoa VC, Wilbe, and angel i... |
| 19.06.2025 | Proxima Fusion: €130 Million Series A Raised For Energy Platform | Proxima Fusion, which is Europe’s fastest-growing fusion energy company, announced the closing of its €130 million ($150 million) Series A financing. The Series A funding was co-led by Cherry Ventures and Balderton Capital. Significant part... |
| 08.11.2024 | Infinitopes: Pioneering the Future of Cancer Vaccines | In the world of cancer treatment, hope often feels like a flickering candle in a storm. Yet, a new player is emerging, determined to turn that flicker into a blazing beacon. Infinitopes, a biotech company born from the halls of Oxford Unive... |
| 08.11.2024 | The Future of Vision and Immunotherapy: Innovations from AllFocal Optics and Infinitopes | In the world of technology and healthcare, two companies are pushing boundaries. AllFocal Optics and Infinitopes are not just making waves; they are creating tsunamis of innovation. Each is tackling a unique challenge: enhancing human visio... |
| 08.11.2024 | Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial | Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line patients with surgically rese... |
| 13.09.2024 | Draghi report sounds alarm on Europe's competitive decline | This week, the European Union released a report about the future of European competitiveness authored by Mario Draghi, former Italian prime minister and president of the European Central Bank. The nearly 400-page report, a year in the makin... |
| 11.04.2024 | Proxima Fusion: A Stellar Rise in the Nuclear Fusion Race | In the competitive world of nuclear fusion startups, Proxima Fusion has emerged as a rising star, securing a hefty $21 million in funding to propel its innovative 'stellarator' approach to fusion energy. While the fusion industry has seen i... |
Show more